The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared to Aspirin in Patients Chronic Vascular Disease.

Jan Steffel,John W. Eikelboom,Sonia S. Anand,Olga Shestakovska,Salim Yusuf,Keith A.A. Fox

The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared to Aspirin in Patients Chronic Vascular Disease.

2020

Jan Steffel
John W. Eikelboom
Sonia S. Anand
Olga Shestakovska
Salim Yusuf
Keith A.A. Fox

Background: Rivaroxaban 2.5mg twice daily plus aspirin 100mg reduced the risk of cardiovascular events as compared to aspirin monotherapy in the COMPASS (Cardiovascular Outcomes for People Using An...

Keywords:

Internal medicine
Rivaroxaban
Medicine
Vascular disease
Aspirin
Cardiology
low dose
Diabetes mellitus
in patient
cardiovascular outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations